DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening
NCT ID: NCT05290428
Last Updated: 2022-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
459 participants
OBSERVATIONAL
2022-03-12
2022-12-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cervical Cytology DNA Methylation for Cervical Cancer Screening
NCT06557954
DNA Methylation for Screening Uterine Cervical Lesions
NCT03960879
DNA Methylation for Screening Uterine Cervical Lesions: A Case-control Study
NCT03961191
Cervical Cancer Screening Strategies
NCT05309122
Host DNA Methylation for Endometrial Cancer Screening
NCT05290415
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Retrospective part
This part will enroll at least 120 cases in previously preserved samples.
DNA methylation testing
All cervical cytology samples will be tested for PAX1 and JAM3 methylation
Prospective part
This part will enroll at least 339 cases.
DNA methylation testing
All cervical cytology samples will be tested for PAX1 and JAM3 methylation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA methylation testing
All cervical cytology samples will be tested for PAX1 and JAM3 methylation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 years or older
* With accessible histological results of cervix
* Signed an approved informed consents
* With accessible cervical cytology before harvesting cervical histology
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhejiang Provincial People's Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Peking Union Medical College Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lei Li
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lei Li, M.D.
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lei Li
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
METHY4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.